Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Differentiation of Essential Oils Using Nanofluidic Protein Post-Translational Modification Profiling.

Urasaki Y, Le TT.

Molecules. 2019 Jun 27;24(13). pii: E2383. doi: 10.3390/molecules24132383.

2.
3.

Quantitative Assessment of Liver Steatosis and Affected Pathways with Molecular Imaging and Proteomic Profiling.

Urasaki Y, Zhang C, Cheng JX, Le TT.

Sci Rep. 2018 Feb 26;8(1):3606. doi: 10.1038/s41598-018-22082-6.

4.

Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib.

Nishiya Y, Nakai D, Urasaki Y, Takakusa H, Ohsuki S, Iwano Y, Yasukochi T, Takayama T, Bazyo S, Oza C, Kurihara A, Savage RE, Izumi T.

Xenobiotica. 2016 Nov;46(11):967-76. doi: 10.3109/00498254.2016.1144896. Epub 2016 Feb 22.

PMID:
26899628
5.

Chronic Uridine Administration Induces Fatty Liver and Pre-Diabetic Conditions in Mice.

Urasaki Y, Pizzorno G, Le TT.

PLoS One. 2016 Jan 20;11(1):e0146994. doi: 10.1371/journal.pone.0146994. eCollection 2016.

6.

Molecular classification of fatty liver by high-throughput profiling of protein post-translational modifications.

Urasaki Y, Fiscus RR, Le TT.

J Pathol. 2016 Apr;238(5):641-50. doi: 10.1002/path.4685. Epub 2016 Feb 25.

PMID:
26725750
7.

Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.

Sakai T, Masaki Y, Otsuki N, Sakamaki I, Kishi S, Miyazono T, Urasaki Y, Murakami J, Satoh T, Nakamura T, Iwao H, Nakajima A, Kawanami T, Miki M, Fujita Y, Tanaka M, Fukushima T, Okazaki T, Ueda T.

Med Oncol. 2015 Sep;32(9):232. doi: 10.1007/s12032-015-0677-9. Epub 2015 Aug 15.

8.

Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.

Takai M, Yamauchi T, Matsuda Y, Tai K, Ikegaya S, Kishi S, Urasaki Y, Yoshida A, Iwasaki H, Ueda T.

Oncol Lett. 2015 May;9(5):2119-2125. Epub 2015 Mar 3.

9.

Capillary Isoelectric Focusing Immunoassay for Fat Cell Differentiation Proteomics.

Johlfs MG, Gorjala P, Urasaki Y, Le TT, Fiscus RR.

PLoS One. 2015 Jul 1;10(7):e0132105. doi: 10.1371/journal.pone.0132105. eCollection 2015.

10.

Associations between oral complications and days to death in palliative care patients.

Matsuo K, Watanabe R, Kanamori D, Nakagawa K, Fujii W, Urasaki Y, Murai M, Mori N, Higashiguchi T.

Support Care Cancer. 2016 Jan;24(1):157-161. doi: 10.1007/s00520-015-2759-9. Epub 2015 May 12.

PMID:
25962615
11.

The response to induction therapy is crucial for the treatment outcomes of elderly patients with acute myeloid leukemia: single-institution experience.

Tasaki T, Yamauchi T, Matsuda Y, Takai M, Ookura M, Lee S, Tai K, Ikegaya S, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.

Anticancer Res. 2014 Oct;34(10):5631-6.

PMID:
25275066
12.

Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome.

Takai M, Yamauchi T, Fujita K, Lee S, Ookura M, Kishi S, Urasaki Y, Yoshida A, Iwasaki H, Ueda T.

Oncol Lett. 2014 Oct;8(4):1523-1527. Epub 2014 Jul 30.

13.

Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.

Tsuji K, Kishi S, Tsuchida T, Yamauchi T, Ikegaya S, Urasaki Y, Fujiwara Y, Ueda T, Okazawa H, Kimura H.

J Magn Reson Imaging. 2015 Jun;41(6):1601-7. doi: 10.1002/jmri.24714. Epub 2014 Aug 11.

PMID:
25111444
14.

Uridine affects liver protein glycosylation, insulin signaling, and heme biosynthesis.

Urasaki Y, Pizzorno G, Le TT.

PLoS One. 2014 Jun 11;9(6):e99728. doi: 10.1371/journal.pone.0099728. eCollection 2014.

15.

Uridine prevents tamoxifen-induced liver lipid droplet accumulation.

Le TT, Urasaki Y, Pizzorno G.

BMC Pharmacol Toxicol. 2014 May 23;15:27. doi: 10.1186/2050-6511-15-27.

16.

Clinical usefulness of the PAXgene™ bone marrow RNA system for stabilizing total RNA.

Takeda M, Funato T, Ikemoto M, Nanmoku T, Urasaki Y, Iwatani Y.

J Clin Lab Anal. 2015 Jan;29(1):61-7. doi: 10.1002/jcla.21729. Epub 2014 Mar 28.

PMID:
24687367
17.

Uridine prevents fenofibrate-induced fatty liver.

Le TT, Urasaki Y, Pizzorno G.

PLoS One. 2014 Jan 24;9(1):e87179. doi: 10.1371/journal.pone.0087179. eCollection 2014.

18.

A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia.

Yamauchi T, Negoro E, Lee S, Takai M, Matsuda Y, Takagi K, Kishi S, Tai K, Hosono N, Tasaki T, Ikegaya S, Inai K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.

Anticancer Res. 2013 Sep;33(9):3947-51.

PMID:
24023333
19.

Detectable Wilms' tumor-1 transcription at treatment completion is associated with poor prognosis of acute myeloid leukemia: a single institution's experience.

Yamauchi T, Negoro E, Lee S, Takai M, Matsuda Y, Takagi K, Kishi S, Tai K, Hosono N, Tasaki T, Ikegaya S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.

Anticancer Res. 2013 Aug;33(8):3335-40.

PMID:
23898100
20.

Disruption of uridine homeostasis links liver pyrimidine metabolism to lipid accumulation.

Le TT, Ziemba A, Urasaki Y, Hayes E, Brotman S, Pizzorno G.

J Lipid Res. 2013 Apr;54(4):1044-57. doi: 10.1194/jlr.M034249. Epub 2013 Jan 24.

21.

Utility of PCR amplification and DNA microarray hybridization of 16S rDNA for rapid diagnosis of bacteremia associated with hematological diseases.

Negoro E, Iwasaki H, Tai K, Ikegaya S, Takagi K, Kishi S, Yamauchi T, Yoshida A, Urasaki Y, Shimadzu M, Ueda T.

Int J Infect Dis. 2013 Apr;17(4):e271-6. doi: 10.1016/j.ijid.2012.10.010. Epub 2012 Dec 8.

22.

Label-free evaluation of hepatic microvesicular steatosis with multimodal coherent anti-Stokes Raman scattering microscopy.

Le TT, Ziemba A, Urasaki Y, Brotman S, Pizzorno G.

PLoS One. 2012;7(11):e51092. doi: 10.1371/journal.pone.0051092. Epub 2012 Nov 30.

23.

Detection of lipid-rich prostate circulating tumour cells with coherent anti-Stokes Raman scattering microscopy.

Mitra R, Chao O, Urasaki Y, Goodman OB, Le TT.

BMC Cancer. 2012 Nov 21;12:540. doi: 10.1186/1471-2407-12-540.

24.

Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma.

Yamauchi T, Matsuda Y, Takai M, Tasaki T, Tai K, Hosono N, Negoro E, Ikegaya S, Takagi K, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.

Anticancer Res. 2012 Nov;32(11):5051-7.

PMID:
23155278
25.

Wilms' tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia.

Yamauchi T, Matsuda Y, Takai M, Tasaki T, Hosono N, Negoro E, Ikegaya S, Takagi K, Kishi S, Yoshida A, Urasaki Y, Ueda T.

Anticancer Res. 2012 Oct;32(10):4479-83.

PMID:
23060576
26.

Imaging immune and metabolic cells of visceral adipose tissues with multimodal nonlinear optical microscopy.

Urasaki Y, Johlfs MG, Fiscus RR, Le TT.

PLoS One. 2012;7(6):e38418. doi: 10.1371/journal.pone.0038418. Epub 2012 Jun 11.

27.

Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells.

Yamauchi T, Matsuda Y, Tasaki T, Negoro E, Ikegaya S, Takagi K, Yoshida A, Urasaki Y, Ueda T.

Cancer Sci. 2012 Sep;103(9):1722-9. doi: 10.1111/j.1349-7006.2012.02343.x. Epub 2012 Jul 11.

28.

Coupling of glucose deprivation with impaired histone H2B monoubiquitination in tumors.

Urasaki Y, Heath L, Xu CW.

PLoS One. 2012;7(5):e36775. doi: 10.1371/journal.pone.0036775. Epub 2012 May 16.

29.
30.

Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes.

Yoshida A, Zokumasu K, Wano Y, Yamauchi T, Imamura S, Takagi K, Kishi S, Urasaki Y, Tohyama K, Ueda T.

Haematologica. 2012 Sep;97(9):1372-9. doi: 10.3324/haematol.2011.055681. Epub 2012 Mar 14.

31.

A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.

Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T, Sugiyama T, Nakao S, Origasa H, Umehara H, Ueda T.

Anticancer Res. 2012 Feb;32(2):643-7.

PMID:
22287757
32.

Clinical utility of the neutrophil distribution pattern obtained using the CELL-DYN SAPPHIRE hematology analyzer for the diagnosis of myelodysplastic syndrome.

Inaba T, Yuki Y, Yuasa S, Fujita N, Yoshitomi K, Kamisako T, Torii K, Okada T, Urasaki Y, Ueda T, Tohyama K.

Int J Hematol. 2011 Aug;94(2):169-177. doi: 10.1007/s12185-011-0892-x. Epub 2011 Jul 6.

PMID:
21732036
33.

Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.

Negoro E, Yamauchi T, Urasaki Y, Nishi R, Hori H, Ueda T.

Int J Oncol. 2011 Apr;38(4):911-9. doi: 10.3892/ijo.2011.933. Epub 2011 Feb 2.

PMID:
21290089
34.

Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines.

Abe M, Havre PA, Urasaki Y, Ohnuma K, Morimoto C, Dang LH, Dang NH.

BMC Cancer. 2011 Feb 1;11:51. doi: 10.1186/1471-2407-11-51.

35.

Glutathione S-transferase M1 inhibits dexamethasone-induced apoptosis in association with the suppression of Bim through dual mechanisms in a lymphoblastic leukemia cell line.

Hosono N, Kishi S, Iho S, Urasaki Y, Yoshida A, Kurooka H, Yokota Y, Ueda T.

Cancer Sci. 2010 Mar;101(3):767-73. doi: 10.1111/j.1349-7006.2009.01432.x. Epub 2010 Jan 7.

36.

CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion.

Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH.

Br J Cancer. 2009 Sep 15;101(6):983-91. doi: 10.1038/sj.bjc.6605236. Epub 2009 Aug 4.

37.

Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.

Yamauchi T, Negoro E, Kishi S, Takagi K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.

Biochem Pharmacol. 2009 Jun 15;77(12):1780-6. doi: 10.1016/j.bcp.2009.03.011. Epub 2009 Mar 24.

PMID:
19428333
38.

[Multicenter collaborative studies by Hokuriku Hematology Oncology Study Group].

Urasaki Y.

Rinsho Ketsueki. 2008 Jul;49(7):469-72. Japanese. No abstract available.

PMID:
18709977
39.

The role of CD26/dipeptidyl peptidase IV in cancer.

Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH.

Front Biosci. 2008 Jan 1;13:1634-45. Review.

PMID:
17981655
40.

Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.

Yamauchi T, Negoro E, Arai H, Ikegaya S, Takagi K, Takemura H, Inai K, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.

Anticancer Res. 2007 Jul-Aug;27(4C):2635-9.

41.

[Chemotherapy of hematological malignancy; principles of treatment].

Ueda T, Urasaki Y.

Nihon Rinsho. 2007 Jan 28;65 Suppl 1:363-8. Review. Japanese. No abstract available.

PMID:
17474433
42.

Enantioselective determination of azelnidipine in human plasma using liquid chromatography-tandem mass spectrometry.

Kawabata K, Samata N, Urasaki Y, Fukazawa I, Uchida N, Uchida E, Yasuhara H.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):389-97. Epub 2007 Feb 15.

PMID:
17350354
43.

Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.

Yamamoto S, Yamauchi T, Kawai Y, Takemura H, Kishi S, Yoshida A, Urasaki Y, Iwasaki H, Ueda T.

Int J Hematol. 2007 Feb;85(2):108-15.

PMID:
17321987
44.
45.

Collaborative action of NF-kappaB and p38 MAPK is involved in CpG DNA-induced IFN-alpha and chemokine production in human plasmacytoid dendritic cells.

Osawa Y, Iho S, Takauji R, Takatsuka H, Yamamoto S, Takahashi T, Horiguchi S, Urasaki Y, Matsuki T, Fujieda S.

J Immunol. 2006 Oct 1;177(7):4841-52.

46.

INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T.

Blood. 2007 Jan 1;109(1):306-14. Epub 2006 Sep 5.

47.

Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7.

Inamoto S, Iwata S, Inamoto T, Nomura S, Sasaki T, Urasaki Y, Hosono O, Kawasaki H, Tanaka H, Dang NH, Morimoto C.

Oncogene. 2007 Feb 8;26(6):893-904. Epub 2006 Aug 7.

PMID:
16909115
48.

Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry.

Kawabata K, Urasaki Y.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 21;844(1):45-52. Epub 2006 Jul 18.

PMID:
16854634
49.

Erythromycin differentially inhibits lipopolysaccharide- or poly(I:C)-induced but not peptidoglycan-induced activation of human monocyte-derived dendritic cells.

Yasutomi M, Ohshima Y, Omata N, Yamada A, Iwasaki H, Urasaki Y, Mayumi M.

J Immunol. 2005 Dec 15;175(12):8069-76.

50.

Nedd9 protein, a Cas-L homologue, is upregulated after transient global ischemia in rats: possible involvement of Nedd9 in the differentiation of neurons after ischemia.

Sasaki T, Iwata S, Okano HJ, Urasaki Y, Hamada J, Tanaka H, Dang NH, Okano H, Morimoto C.

Stroke. 2005 Nov;36(11):2457-62. Epub 2005 Oct 6.

PMID:
16210561

Supplemental Content

Loading ...
Support Center